Myeloproliferative Neoplasms

What are myeloproliferative neoplasms?

Myeloproliferative neoplasms (often shortened to MPNs) are a group of slow-growing blood cancers that begin in the bone marrow, the soft tissue inside bones where blood cells are made. In an MPN, a change in a marrow stem cell (an immature cell that can develop into any type of blood cell) causes the marrow to produce too many of one or more kinds of blood cells. Depending on the type, the excess may involve red blood cells (which carry oxygen), white blood cells (which fight infection), or platelets (small cell fragments that help blood clot).

The word myeloproliferative simply means “overgrowth of marrow cells,” and neoplasm means an abnormal growth of cells. These conditions are considered chronic, which means they develop slowly and are usually managed over many years rather than cured quickly.

The main types of myeloproliferative neoplasms include:

• Polycythemia vera – the marrow makes too many red blood cells, and often too many white cells and platelets as well.
• Essential thrombocythemia – the marrow makes too many platelets.
• Primary myelofibrosis – scar tissue gradually builds up inside the marrow, so it struggles to make normal blood cells.
• Chronic myeloid leukemia – a type of leukemia marked by a specific genetic change called the Philadelphia chromosome, which drives overproduction of white blood cells.
• Rarer forms, such as chronic neutrophilic leukemia and chronic eosinophilic leukemia, in which particular types of white blood cells are overproduced.

MPNs are relatively uncommon. They are diagnosed most often in older adults, typically in middle age or later, although they can occur at any age, including in young adults. Men and women are both affected. Care for these conditions is usually led by a hematologist, a doctor who specializes in blood disorders; within Acibadem hospitals this is managed through the Hematology Department.

Myeloproliferative neoplasms symptoms

Many people have no symptoms at first. It is common for an MPN to be discovered when a routine blood test shows abnormal cell counts. When symptoms do appear, they are often vague and can be mistaken for other problems. Common myeloproliferative neoplasms symptoms include:

• Ongoing tiredness or weakness that does not improve with rest
• Headaches, dizziness, or lightheadedness
• Blurred vision or other visual disturbances
• Itching, especially after a warm bath or shower (most typical of polycythemia vera)
• Night sweats and unexplained fever
• Unintended weight loss or poor appetite
• A feeling of fullness or discomfort under the left ribs, caused by an enlarged spleen (an organ that filters blood)
• Easy bruising or bleeding, such as nosebleeds or bleeding gums
• Burning pain, redness, or tingling in the hands and feet
• Bone pain or aching in the joints
• Shortness of breath

Symptoms often differ by type. In polycythemia vera, the blood becomes thicker because of the excess red cells, which can cause headaches, a flushed face, itching, and a higher chance of blood clots. In essential thrombocythemia, many people feel well, but the high platelet count can lead to either clotting or, paradoxically, bleeding. In primary myelofibrosis, the failing marrow often causes anemia (too few red blood cells), leading to fatigue and breathlessness, along with a noticeably enlarged spleen, night sweats, and weight loss. Chronic myeloid leukemia may cause fatigue, sweating, and spleen enlargement, and in its early phase is often found by chance.

Over time, some MPNs can progress. Polycythemia vera and essential thrombocythemia may, in a minority of people, develop into myelofibrosis. Any MPN can, less commonly, transform into acute leukemia, a faster-growing blood cancer. Symptoms tend to become more pronounced as the condition advances, which is one reason regular monitoring matters.

Causes and risk factors

Myeloproliferative neoplasms causes are not fully understood, but research has shown that most cases are driven by acquired changes (mutations) in the genes of a marrow stem cell. These changes are not usually inherited from a parent; they develop during a person’s lifetime. The most frequently involved genes include:

• JAK2 – a gene that helps control how blood cells grow and divide. A JAK2 mutation is found in the large majority of people with polycythemia vera and in a substantial share of those with essential thrombocythemia or primary myelofibrosis.
• CALR and MPL – genes that, when altered, are found in many people with essential thrombocythemia or myelofibrosis who do not have a JAK2 mutation.
• BCR-ABL1 – the abnormal gene created by the Philadelphia chromosome, which defines chronic myeloid leukemia.

These mutations switch on signals that tell the marrow to keep making blood cells even when the body does not need more. Why these changes occur in a given person is usually unknown.

Factors that may raise the risk of developing an MPN include:

• Older age – risk increases with age, although younger people can be affected.
• Family history – having a close relative with an MPN slightly increases risk, suggesting some inherited tendency in certain families, even though the condition itself is not directly passed down.
• Exposure to high doses of radiation – for example, from certain past medical treatments or accidents.
• Exposure to certain chemicals, such as benzene, over long periods.
• Sex – some types are slightly more common in men, others in women.

Most people with these risk factors never develop an MPN, and many people with an MPN have no known risk factors. Lifestyle choices are not thought to cause these conditions.

Myeloproliferative neoplasms diagnosis

Because early symptoms are often absent or mild, myeloproliferative neoplasms diagnosis frequently starts with an unexpected result on a routine blood test. From there, doctors use a combination of tests to confirm the type of MPN and rule out other explanations, such as infection, iron deficiency, inflammation, or dehydration, which can also alter blood counts.

• Complete blood count (CBC) – measures the numbers of red cells, white cells, and platelets, and the hemoglobin level (the oxygen-carrying protein in red cells). Persistently high counts are the first clue.
• Peripheral blood smear – a drop of blood is examined under a microscope to look at the size and shape of blood cells.
• Genetic (molecular) testing – blood or marrow is tested for mutations in JAK2, CALR, MPL, and for the BCR-ABL1 gene. Finding one of these strongly supports the diagnosis and helps identify the type.
• Bone marrow aspiration and biopsy – a small sample of liquid marrow and a tiny core of bone are taken, usually from the back of the hip under local anesthetic, and examined for the pattern of cell growth and for scarring (fibrosis). This is often needed to distinguish between types and to assess how advanced the condition is.
• Erythropoietin level – a blood test for the hormone that stimulates red cell production; a low level in someone with high red cells points toward polycythemia vera.
• Imaging – an ultrasound or CT scan of the abdomen may be used to measure the spleen and liver.
• Additional blood tests – such as iron studies, kidney and liver function, and uric acid, to rule out other causes and check overall health.

Doctors compare these findings with internationally agreed diagnostic criteria, such as those published by the World Health Organization, which set out the combination of blood count thresholds, marrow findings, and genetic results needed to confirm each type of MPN. Results are usually reviewed by a hematologist together with a pathologist (a doctor who examines tissue samples).

Myeloproliferative neoplasms treatment options

Myeloproliferative neoplasms treatment aims to control blood counts, relieve symptoms, lower the risk of complications such as blood clots or bleeding, and, where possible, slow progression. The right approach depends on the type of MPN, the person’s age and general health, their symptoms, and their individual risk of clotting. Treatment is usually long-term and is adjusted over time.

Observation and monitoring

For people at low risk with few or no symptoms, especially with essential thrombocythemia, doctors may recommend regular check-ups and blood tests without immediate drug treatment. This is sometimes called watchful waiting or active surveillance.

Medications

• Low-dose aspirin – often used to reduce the risk of blood clots in polycythemia vera and essential thrombocythemia, when it is considered safe for the individual.
• Cytoreductive drugs – medicines that lower the number of blood cells the marrow produces. Hydroxyurea (also called hydroxycarbamide) is commonly used. Interferon-based drugs are another option, sometimes preferred for younger people or during pregnancy planning. Anagrelide may be used specifically to lower platelets.
• JAK inhibitors – targeted drugs, such as ruxolitinib, that block the overactive signaling caused by JAK2-related changes. They are used mainly in myelofibrosis, and in some cases of polycythemia vera, to shrink the spleen and ease symptoms such as night sweats and itching.
• Tyrosine kinase inhibitors – targeted drugs such as imatinib that block the BCR-ABL1 protein in chronic myeloid leukemia. These have changed the outlook for this condition and are usually taken long-term as tablets.
• Supportive medicines – for example, treatment for anemia, drugs to control itching, or medicines to manage high uric acid.

Procedures

• Phlebotomy – the removal of a set amount of blood through a vein, similar to donating blood. In polycythemia vera this lowers the red cell count and makes the blood less thick. It is often repeated at intervals.
• Blood transfusions – may be needed in myelofibrosis when anemia is severe.
• Radiation therapy to the spleen – occasionally used to reduce spleen size when other measures have not helped.

Surgery

Surgical removal of the spleen (splenectomy) is uncommon but may be considered in myelofibrosis when a very large spleen causes severe pain, poor eating, or worsening blood counts that do not respond to medicine. It carries its own risks, so the decision is weighed carefully.

Stem cell transplant

An allogeneic stem cell transplant, in which the person’s marrow is replaced with healthy stem cells from a donor, is currently the only treatment with the potential to cure myelofibrosis and some other MPNs. It is an intensive treatment with significant risks, so it is generally reserved for younger or fitter people with higher-risk disease. Your doctor may discuss whether it is appropriate in your situation.

Supportive care and rehabilitation

Managing fatigue, maintaining nutrition, staying physically active as tolerated, and addressing emotional wellbeing are all part of care. Many centers offer access to dietitians, physiotherapists, and counseling services alongside medical treatment.

Living with myeloproliferative neoplasms and outlook

For most people, an MPN is a long-term condition rather than an immediate threat to life. Many people with polycythemia vera or essential thrombocythemia live for many years, often decades, with treatment focused on preventing clots and controlling symptoms. Chronic myeloid leukemia, once a serious diagnosis, is now often controlled for long periods with daily targeted tablets. Primary myelofibrosis tends to be more variable; some people remain stable for years, while others experience faster progression. Outcomes depend heavily on the type, the person’s age and health, the specific genetic changes involved, and how the condition responds to treatment, so no general statement can predict an individual’s course.

Living well with an MPN usually involves:

• Attending regular appointments and blood tests, even when you feel well, so that changes can be caught early.
• Taking medicines consistently and reporting side effects rather than stopping on your own.
• Reducing other clotting risks: not smoking, managing blood pressure, cholesterol, and diabetes, staying hydrated, and keeping physically active within your limits.
• Telling any doctor, dentist, or surgeon about your condition before procedures, because bleeding and clotting risks may need special planning.
• Pacing activities to manage fatigue, and asking for help with sleep problems, itching, or mood changes.
• Seeking support from patient organizations or counseling if the uncertainty of a chronic condition feels heavy.

Doctors use scoring systems that combine age, blood counts, symptoms, and genetic findings to estimate risk and guide treatment decisions. These are tools for planning care, not fixed predictions, and your hematologist can explain what they mean for you.

Frequently asked questions

Are myeloproliferative neoplasms a type of cancer?

Yes. Myeloproliferative neoplasms are classified as blood cancers because they involve uncontrolled growth of abnormal marrow cells. However, they are usually chronic and slow-growing, and many people live with them for a long time. The word “cancer” can be alarming, so it may help to ask your doctor to explain how your particular type typically behaves.

What are the first symptoms of myeloproliferative neoplasms?

Often there are none, and the condition is found on a routine blood test. When early myeloproliferative neoplasms symptoms do occur, they are usually mild and nonspecific, such as tiredness, headaches, dizziness, itching after bathing, or a sense of fullness on the left side of the abdomen. Because these can have many causes, only testing can determine whether an MPN is responsible.

What causes myeloproliferative neoplasms, and are they inherited?

Most myeloproliferative neoplasms causes come down to acquired genetic changes, most commonly in the JAK2, CALR, MPL, or BCR-ABL1 genes, that arise in a single marrow stem cell during a person’s life. These mutations are not usually passed from parent to child. A family history does slightly raise risk, which suggests some inherited susceptibility in certain families, but the disease itself is not directly hereditary in most cases.

How are myeloproliferative neoplasms diagnosed?

Myeloproliferative neoplasms diagnosis relies on blood counts, examination of blood cells under a microscope, genetic testing for the known mutations, and in many cases a bone marrow biopsy. Imaging of the spleen and other blood tests help complete the picture. Doctors then apply standardized diagnostic criteria to confirm the type of MPN.

Can myeloproliferative neoplasms be cured?

At present, a stem cell transplant from a donor is the only treatment with the potential to cure most MPNs, and it is suitable only for selected people because of its risks. For the majority, myeloproliferative neoplasms treatment focuses on controlling counts and symptoms and preventing complications, which many people achieve for long periods. Chronic myeloid leukemia can often be kept in deep remission with targeted tablets, and some people are able to stop treatment under close supervision.

What is the life expectancy for someone with a myeloproliferative neoplasm?

This varies widely by type and individual. People with essential thrombocythemia or polycythemia vera often have a life expectancy close to that of the general population when the condition is well managed, while primary myelofibrosis tends to be more serious and more variable. Your hematologist can discuss your outlook based on your specific diagnosis, risk score, and response to treatment, but no one can give guarantees.

Do myeloproliferative neoplasms always get worse?

Not necessarily. Many people remain stable for years. In some cases, polycythemia vera or essential thrombocythemia can progress to myelofibrosis, and any MPN can, less commonly, transform into acute leukemia. Regular monitoring is intended to detect any such change early so that treatment can be adjusted.

When to see a doctor

If you have persistent, unexplained symptoms such as ongoing fatigue, frequent headaches, itching after bathing, night sweats, unexplained weight loss, easy bruising, or a feeling of fullness under your left ribs, it is reasonable to ask a doctor for an evaluation that includes a blood count. If you have already been diagnosed with an MPN, keep to your scheduled follow-up and tell your care team about any new or changing symptoms.

Seek emergency medical care immediately if you or someone with an MPN experiences any of the following, which may indicate a blood clot, serious bleeding, or another urgent complication:

• Sudden chest pain, pressure, or shortness of breath
• Sudden weakness or numbness of the face, arm, or leg, trouble speaking, or confusion
• Sudden loss of vision or severe, sudden headache
• Pain, swelling, warmth, or redness in one leg or arm
• Severe abdominal pain, especially in the upper abdomen
• Bleeding that will not stop, black or bloody stools, or vomiting blood
• A high fever or shaking chills, particularly while taking treatment that lowers blood counts
• Fainting or a very rapid heartbeat

These signs do not always mean a serious problem, but with an MPN the risk of clotting and bleeding is higher than usual, so prompt assessment is important.